BLAINJECTIONINJECTABLE
Approved
Jul 2018
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
2/8 — Basic
NIVESTYM (filgrastim-aafi) by Pfizer is colony-stimulating factors are glycoproteins which act on hematopoietic cells by binding to specific cell surface receptors and stimulating proliferation, differentiation commitment, and some end-cell functional activation. First approved in 2018.
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NIVESTYM (filgrastim-aafi) is a biosimilar granulocyte colony-stimulating factor (G-CSF) approved in 2018 that stimulates neutrophil production in the bone marrow by binding to cell surface receptors. It is used to reduce the duration of neutropenia and associated complications in patients receiving myelosuppressive chemotherapy or undergoing bone marrow transplantation. The drug works by promoting proliferation, differentiation, and functional activation of neutrophil progenitor cells.
Peak
As a biosimilar in peak lifecycle stage with moderate competitive pressure (30/100), the brand team is likely stable but focused on maintaining market share against reference biologics and competing biosimilars.
Mechanism of Action
Colony-stimulating factors are glycoproteins which act on hematopoietic cells by binding to specific cell surface receptors and stimulating proliferation, differentiation commitment, and some end-cell functional activation. Endogenous G-CSF is a lineage-specific colony-stimulating factor that is…
Pharmacologic Class:
Leukocyte Growth Factor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on NIVESTYM offers exposure to biosimilar commercial strategy, payer negotiation, and oncology supportive care markets within Pfizer's established infrastructure. The peak lifecycle stage indicates a mature, well-resourced franchise with stable team composition but limited growth opportunities compared to early-stage launches.
Worked on NIVESTYM at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.